Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV-1, Drug Administration Schedule, AIDS Vaccines, CD4 Lymphocyte Count, RNA, Viral, Anti-HIV Agents, Viral Load, HIV Therapeutic Vaccine, Treatment Interruption
Eligibility Criteria
Inclusion Criteria for Step 1 HIV infection CD4 count greater than 400 cells/mm3 within 6 months before study entry Current, persistent viral load below 400 copies/ml for 6 months before study entry and under 50 copies/ml at study screening Currently receiving their first combination ART regimen (3 or more antiretrovirals) for at least 4 weeks before screening, or if the current potent ART regimen is not their first potent ART regimen, must have been receiving the current regimen for at least 4 weeks prior to screening Negative pregnancy test within 45 days before study entry Acceptable methods of contraception Provide informed consent Exclusion Criteria Immunomodulators within 45 days of study entry such as systemic corticosteroids, interferons, interleukins, thalidomide, sargramostim (granulocyte-macrophage colony-stimulating factor [GM-CSF]), dinitrochlorobenzene (DNCB), thymosin alpha, thymopentin, inosiplex, polyribonucleoside, and ditiocarb sodium Abacavir within 8 weeks of study entry Infection or medical illness within 14 days of study entry Cancer that may require systemic therapy History of lymph node radiation therapy Prior HIV vaccine Received hydroxyurea within 45 days of study entry Close contact with canaries through work (e.g., breeding farms, bird shops); patients with a pet canary are not excluded Abuse or dependence on drugs or alcohol Allergic to albumin Pregnant or breastfeeding Infected with HIV within 1 year of study entry Interruption of potent ART for more than 7 consecutive days within 1 year of study entry History of allergy to egg proteins or neomycin History of other serious acute allergic reactions (e.g., anaphylaxis, allergy-induced asthma, Stevens-Johnson syndrome, toxic epidermal necrolysis)
Sites / Locations
- Alabama Therapeutics CRS
- UCLA CARE Center CRS
- Ucsf Aids Crs
- Indiana Univ. School of Medicine, Infectious Disease Research Clinic
- Washington U CRS
- Beth Israel Med. Ctr., ACTU
- NY Univ. HIV/AIDS CRS
- AIDS Care CRS
- Univ. of Rochester ACTG CRS
- Unc Aids Crs
- Case CRS
- The Ohio State University Medical Center
- Hosp. of the Univ. of Pennsylvania CRS
- Univ. of Pennsylvania Health System, Presbyterian Med. Ctr.
- The Miriam Hosp. ACTG CRS
- University of Washington AIDS CRS